# Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

> **NCT05757219** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 27 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Itacitinib
- **BIOLOGICAL:** Chimeric antigen receptor (CAR) T-cell therapy

## Key facts

- **NCT ID:** NCT05757219
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-19
- **Primary completion:** 2026-06-20
- **Final completion:** 2027-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757219, "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05757219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*